Louise C. Strong, M.D.
Department of Genetics, Division of Basic Sciences
Present Title & Affiliation
Primary Appointment
Professor, Department of Genetics, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Sue and Radcliffe Killam Distinguished Chair, Department of Genetics, Division of Basic Science Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Ann Parsons Foundation, Distinguished Professor, Genetics of Pediatric Cancers, Department of Pediatrics - Research, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences, Houston, TX
Research Interests
Human cancer genetics Genetic epidemiology
The program involves the study of genetic etiology of human cancer using genetic epidemiologic approach to identify the most likely etiologic model(s) to account for the distribution of tumors in kindreds, and to test for genetic/etiologic heterogeneity. We then identify families in which a genetic etiology seems likely for collaborative study using cytogenetic, biochemical and molecular markers to localize the gene. We are further investigating the role of radiation, chemotherapy and host predisposing factors in the risk of subsequent tumors in childhood cancer survivors and in the reproductive outcomes in childhood cancer survivors.
A tutorial in this laboratory would include introduction to field work of data collection by interview, analytic techniques of genetic epidemiology and interpretation of laboratory findings from the collaborative laboratory studies.
View a complete list of Dr. Strong's publications.
Visit Dr. Strong’s Li Fraumeni Syndrome Study Group website.
Education & Training
Degree-Granting Education
| 1970 | University of Texas Medical Branch, Galveston, TX, USA, MD, Medicine |
| 1966 | University of Texas, Austin, TX, USA, BA, Mathematics |
Postgraduate Training
| 1970-1972 | Postdoctoral Fellowship, Texas Research Institute of Mental Sciences and The University of Texas Graduate School of Biomedical Sciences, Houston, TX |
Selected Publications
Peer-Reviewed Articles
- Shin SJ, Dodd-Eaton EB, Gao F, Bojadzieva J, Chen J, Kong X, Amos CI, Ning J, Strong LC, Wang W. Penetrance estimates over time to first and second primary cancer diagnosis in families with Li-Fraumeni syndrome: a single institution perspective. Cancer Res 80(2):347-353, 2020. e-Pub 2019. PMID: 31719099.
- Opstal-van Winden AWJ, de Haan HG, Hauptmann M, Schmidt MK, Broeks A, Russell NS, Janus CPM, Krol ADG, van der Baan FH, De Bruin ML, van Eggermond AM, Dennis J, Anton-Culver H, Haiman CA, Sawyer EJ, Cox A, Devilee P, Hooning MJ, Peto J, Couch FJ, Pharoah P, Orr N, Easton DF, Aleman BMP, Strong LC, Bhatia S, Cooke R, Robison LL, Swerdlow AJ, van Leeuwen FE. Genetic susceptibility to radiation-induced breast cancer after Hodgkin lymphoma. Blood 133(10):1130-1139, 2019. e-Pub 2018. PMID: 30573632.
- Swaminathan M, Bannon SA, Routbort M, Naqvi K, Kadia TM, Takahashi K, Alvarado Y, Ravandi-Kashani F, Patel KP, Champlin R, Kantarjian H, Strong L, DiNardo CD. Hematologic malignancies and Li-Fraumeni syndrome. Cold Spring Harb Mol Case Stud 5(1), 2019. e-Pub 2019. PMID: 30709875.
- Shin SJ, Yuan Y, Strong LC, Bojadzieva J, Wang W. Bayesian Semiparametric Estimation of Cancer-Specific Age-at-Onset Penetrance With Application to Li-Fraumeni Syndrome. J Am Stat Assoc 114(526):541-552, 2019. e-Pub 2018. PMID: 31485091.
- Goldsby RE, Stratton KL, Raber S, Ablin A, Strong LC, Oeffinger K, Sklar CA, Armstrong GT, Robison LL, Bhatia S, Leisenring WM. Long-term sequelae in survivors of childhood leukemia with Down syndrome: A childhood cancer survivor study report. Cancer 124(3):617-625, 2018. e-Pub 2017. PMID: 29105081.
- Morton LM, Sampson JN, Armstrong GT, Chen TH, Hudson MM, Karlins E, Dagnall CL, Li SA, Wilson CL, Srivastava DK, Liu W, Kang G, Oeffinger KC, Henderson TO, Moskowitz CS, Gibson TM, Merino DM, Wong JR, Hammond S, Neglia JP, Turcotte LM, Miller J, Bowen L, Wheeler WA, Leisenring WM, Whitton JA, Burdette L, Chung C, Hicks BD, Jones K, Machiela MJ, Vogt A, Wang Z, Yeager M, Neale G, Lear M, Strong LC, Yasui Y, Stovall M, Weathers RE, Smith SA, Howell R, Davies SM, Radloff GA, Onel K, de González AB, Inskip PD, Rajaraman P, Fraumeni JF, Bhatia S, Chanock SJ, Tucker MA, Robison LL. Genome-Wide Association Study to Identify Susceptibility Loci That Modify Radiation-Related Risk for Breast Cancer After Childhood Cancer. J Natl Cancer Inst 109(11), 2017. PMID: 29059430.
- Zhou R, Xu A, Gingold J, Strong LC, Zhao R, Lee DF. Li-Fraumeni syndrome disease model: A platform to develop precision cancer therapy targeting oncogenic p53. Trends Pharmacol Sci 38(10):908-927, 2017. e-Pub 2017. PMID: 28818333.
- Porter CC, Druley TE, Erez A, Kuiper RP, Onel K, Schiffman JD, Wolfe Schneider K, Scollon SR, Scott HS, Strong LC, Walsh MF, Nichols KE. Recommendations for Surveillance for Children with Leukemia-Predisposing Conditions. Clin Cancer Res 23(11):e14-e22, 2017. PMID: 28572263.
- Kratz CP, Achatz MI, Brugières L, Frebourg T, Garber JE, Greer MC, Hansford JR, Janeway KA, Kohlmann WK, McGee R, Mullighan CG, Onel K, Pajtler KW, Pfister SM, Savage SA, Schiffman JD, Schneider KA, Strong LC, Evans DGR, Wasserman JD, Villani A, Malkin D. Cancer Screening Recommendations for Individuals with Li-Fraumeni Syndrome. Clin Cancer Res 23(11):e38-e45, 2017. PMID: 28572266.
- Leroy B, Ballinger ML, Baran-Marszak F, Bond GL, Braithwaite A, Concin N, Donehower LA, El-Deiry WS, Fenaux P, Gaidano G, Langerød A, Hellstrom-Lindberg E, Iggo R, Lehmann-Che J, Mai PL, Malkin D, Moll UM, Myers JN, Nichols KE, Pospisilova S, Ashton-Prolla P, Rossi D, Savage SA, Strong LC, Tonin PN, Zeillinger R, Zenz T, Fraumeni JF, Taschner PE, Hainaut P, Soussi T. Recommended Guidelines for Validation, Quality Control, and Reporting of TP53 Variants in Clinical Practice. Cancer Res 77(6):1250-1260, 2017. e-Pub 2017. PMID: 28254861.
- Daniels M, Wathoo C, Brusco L, Lu KH, Shaw K, Dumbrava EEI, Arun B, Strong L, Litton JK, Eterovic K, Aytac U, Mendelsohn J, Mills GB, Chen K, Meric-Bernstam F. Active Disclosure of Secondary Germline Findings to Deceased Research Participants' Personal Representatives: Process and Outcomes. JCO Precis Oncol 1, 2017. e-Pub 2017. PMID: 31552380.
- Palculict TB, Ruteshouser EC, Fan Y, Wang W, Strong L, Huff V. Identification of germline DICER1 mutations and loss of heterozygosity in familial Wilms tumor using whole genome sequencing. J Med Genet 53(6):385-8, 2016. e-Pub 2015. PMID: 26566882.
- Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AT, Strong LC, Shaw K, Lu K, Qi Y, Lara-Guerra H, Litton J, Arun B, Zhao H, Eterovic AK, Aytac U, Routbort M, Subbiah V, Janku F, Davies D, Kopetz S, Mendelsohn J, Mills GB, Chen K. Incidental germline variants in 1000 advanced cancers on a prospective somatic genomic profiling protocol. Annals of Oncology 27(5):795-800, 2016. PMID: 26787237.
- Malkin D, Garber JE, Strong LC, Friend SH. CANCER. The cancer predisposition revolution. Science 352(6289):1052-3, 2016. PMID: 27230363.
- Henderson TO, Moskowitz CS, Chou JF, Bradbury AR, Neglia JP, Dang CT, Onel K, Novetsky Friedman D, Bhatia S, Strong LC, Stovall M, Kenney LB, Barnea D, Lorenzi E, Hammond S, Leisenring WM, Robison LL, Armstrong GT, Diller LR, Oeffinger KC. Breast cancer risk in childhood cancer survivors without a history of chest radiotherapy: A report from the Childhood Cancer Survivor Study (CCSS). J Clin Oncol 34(9):910-918, 2016. e-Pub 2015. PMID: 26700127.
- Yang XR, Killian JK, Hammond S, Burke LS, Bennett H, Wang Y, Davis SR, Strong LC, Neglia J, Stovall M, Weathers RE, Robison LL, Bhatia S, Mabuchi K, Inskip PD, Meltzer P. Characterization of genomic alterations in radiation-associated breast cancer among childhood cancer survivors, using comparative genomic hybridization (CGH) arrays. PLoS One 10(3):e0116078, 2015. e-Pub 2015. PMID: 25764003.
- Cozen W, Timofeeva MN, Li D, Diepstra A, Hazelett D, Delahaye-Sourdeix M, Edlund CK, Franke L, Rostgaard K, Van Den Berg DJ, Cortessis VK, Smedby KE, Glaser SL, Westra HJ, Robison LL, Mack TM, Ghesquieres H, Hwang AE, Nieters A, de Sanjose S, Lightfoot T, Becker N, Maynadie M, Foretova L, Roman E, Benavente Y, Rand KA, Nathwani BN, Glimelius B, Staines A, Boffetta P, Link BK, Kiemeney L, Ansell SM, Bhatia S, Strong LC, Galan P, Vatten L, Habermann TM, Duell EJ, Lake A, Veenstra RN, Visser L, Liu Y, Urayama KY, Montgomery D, Gaborieau V, Weiss LM, Byrnes G, Lathrop M, Cocco P, Best T, Skol AD, Adami HO, Melbye M, Cerhan JR, Gallagher A, Taylor GM, Slager SL, Brennan P, Coetzee GA, Conti DV, Onel K, Jarrett RF, Hjalgrim H, van den Berg A, McKay JD. A meta-analysis of Hodgkin lymphoma reveals 19p13.3 TCF3 as a novel susceptibility locus. Nat Commun 5:3856, 2014. e-Pub 2014. PMID: 24920014.
- Hill DA, Horick NK, Isaacs C, Domchek SM, Tomlinson GE, Lowery JT, Kinney AY, Berg JS, Edwards KL, Moorman PG, Plon SE, Strong LC, Ziogas A, Griffin CA, Kasten CH, Finkelstein DM. Long-term risk of medical conditions associated with breast cancer treatment. Breast Cancer Res Treat 145(1):233-43, 2014. e-Pub 2014. PMID: 24696430.
- Gramatges MM, Liu Q, Yasui Y, Okcu MF, Neglia JP, Strong LC, Armstrong GT, Robison LL, Bhatia S. Telomere content and risk of second malignant neoplasm in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Clin Cancer Res 20(4):904-11, 2014. e-Pub 2013. PMID: 24277454.
- Pilarski R, Cebulla CM, Massengill JB, Rai K, Rich T, Strong LC, McGillivray B, Asrat M-J, Davidorf FH, Abdel-Rahman MH. Expanding the clinical phenotype of hereditary BAP1 cancer predisposition syndrome. Genes Chromosomes Cancer 53(2):177–182, 2014. e-Pub 2013. PMID: 24243779.
- Powell BC, Jiang L, Muzny DM, Trevino L, Dreyer Z, Strong LC, Wheeler DA,. Gibbs RA, Plon SE. Identification of TP53 as an acute lymphocytic leukemia susceptibility gene through exome sequencing. Pediatr Blood Cancer 60(6):E1-3153, 2013. PMID: 23255406.
- Fang S, Krahe R, Bachinski LL, Zhang B, Amos CI, Strong LC. Sex-specific effect of TP53 PIN3 polymorphism on cancer risk in a cohort study of TP53 germline mutation carriers. Hum Genet 130(6):789-94, 2011. e-Pub 2011. PMID: 21688173.
- Wu, CC, Krahe R, Lozano G, Zhang B, Wilson CD, Jo EJ, Shete S, Amos CI, Strong LC. Joint effects of germ-line TP53 mutation, MDM2 SNP309, and gender on cancer risk in family studies of Li-Fraumeni syndrome. Hum Genet 129(6):663-73, 2011. e-Pub 2011. PMID: 21305319.
- Fang, S, Krahe R, Lozano G, Han Y, Chen W, Post SM, Zhang B, Wilson C, Bachinski LL, Strong LC, Amos CI. Effects of MDM2, MDM4 and TP53 codon 72 polymorphisms on cancer risk in carriers of TP53 germline mutations. PLoS ONE 5(5):e10813, 2010. PMID: 20520810.
- Wu CC, Strong LC, Shete S.. Effects of measured susceptibility genes on cancer risk in family studies. Hum Genet 127(3):349-357, 2010. PMID: 20039063.
- Shin SJ, Li J, Ning J, Bojadzieva J, Strong LC, Wang W. Bayesian estimation of a semiparametric recurrent event model with applications to the penetrance estimation of multiple primary cancers in Li-Fraumeni Syndrome. Biostatistics. e-Pub 2018. PMID: 30445420.
Abstracts
- Dumbrava E, Brusco L, M Daniels, Wathoo, Shaw K, Lu K, Zheng X, Strong et al. Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutations. JCO Precision Oncology, 2019.
Letters to the Editor
- Leroy B, Strong LC, Soussi T. Revised guidelines for screening of TP53 gene mutations. Nature Rev Clin Oncol.